Skip to main content
. 2017 Mar 3;8(24):38530–38540. doi: 10.18632/oncotarget.15869

Figure 4. CYPs gene expression in OS cell lines treated with cisplatin, doxorubicin, methotrexate, cisplatin plus doxorubicin (CD), and cisplatin plus doxorubicin plus methotrexate (CDM).

Figure 4

A. CYP1A2 upregulation by doxorubicin, CD and CDM treatments. B. CYP3A4 upregulation by cisplatin, doxorubicin, methotrexate, CD and CDM treatments, whereas upregulation by methotrexate was time-dependent. C. CYP3A5 downregulation by doxorubicin, CD and CDM treatments, whereas methotrexate upregulated in a time-dependent manner. Statistical significance by Mann-Whitney and Wilcoxon: *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001.